Drugs / GSK4425689A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07646353 | Jun 2026 → Apr 2028 expected | Plasmodium falciparum malaria | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK4425689A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07646353 ↗ |
| Modality | Monoclonal antibody | “GSK4425689A monoclonal antibody (mAb)” NCT07646353 ↗ |
| Route | Intravenous | “administered by either intravenous (IV) or subcutaneous (SC) routes” NCT07646353 ↗ |
| Route | Subcutaneous | “administered by either intravenous (IV) or subcutaneous (SC) routes” NCT07646353 ↗ |